It is widely accepted that progression of clonal plasma cells, from an indolent MGUS phase to the malignant MM phase, is driven by several oncogenic initiators such as Myc structural variants, activating mutations of RAS and NF-κB pathways (114). Here, NFKB1 is linked to Miyoshi myopathy.